VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ...

The 30,000-square-foot New Jersey Innovation Hub at HELIX offers laboratory space and other resources to early-stage ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today provided an update on its strategy and progress to implement ...

King Charles visited a North Yorkshire research facility to review a non-lethal contraceptive project aimed at controlling the invasive grey squirrel population, which threatens Britain's native red ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its ...

Chinese biotechs can run trials 50–70% faster – our report shows where that speed is paying off, and where the road narrows.

Vir Biotechnology Inc. has appointed David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, bringing more than... Read More ...

Biotech Open Platform has inaugurated a new biotechnology platform in Clermont-Ferrand, France, as it seeks to bridge the gap between laboratory development and industrial-scale production while ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will ...

A Nobel prize for optogenetics draws a major biotech opportunity into the spotlight. Genetic data offers a hotbed for medical innovation—if Indian regulation gets its speed-versus-safety trade-off rig ...

Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2 ...

A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...